From the Journals

Refining Vancomycin Use in Early CDI

A modified dosing approach could reshape recurrence prevention strategies.

Share

Clostridioides difficile infection poses significant morbidity and mortality risks, often recurring post-treatment. The TAPER-V trial, spearheaded by Dr. Emily G. McDonald at McGill University, explored a 4-week vancomycin pulse-and-taper regimen for patients with a first episode or recurrence. Results indicated a 74% probability of this approach being superior to a 2-week pulse followed by placebo in preventing recurrences by day 56. Conducted across 12 Canadian hospitals with 265 participants, this trial suggests a promising pathway to improve C. difficile management.

Original Source(s)

Refining Vancomycin Use in Early CDI

A modified dosing approach could reshape recurrence prevention strategies.

  • by Julia Cipriano, MS, CMPP

  • March 4, 2026

  • 2 min

Related Content

Sepsis Antibiotic Timing Shows Physician Divide

Emergency department physicians differ in how quickly they initiate antibiotics for suspected sepsis.

Top 10 States to Practice Infectious Diseases

The following list highlights the states that offer the most favorable conditions for infectious disease physicians.